Form 4: BridgeBio Pharma Director Acquires Stock, Options
Statement of Changes in Beneficial Ownership
BridgeBio Pharma director Fred Hassan acquired restricted stock units and stock options, signaling continued commitment and potential future equity.
Summary
- Fred Hassan, a Director at BridgeBio Pharma, Inc., acquired 3,990 shares of Common Stock through restricted stock units (RSUs) on June 22, 2026.
- These RSUs were granted under the company's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
- The RSUs vest in full on June 22, 2027, contingent upon Hassan's continued service as a director.
- Additionally, Hassan acquired a stock option to buy 5,277 shares of Common Stock at an exercise price of $68.92.
- This stock option also vests in full on June 22, 2027, subject to his continued service.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects a director's continued commitment and investment in the company through equity, but it does not contain operational or financial performance updates.
Positives
- Director Fred Hassan's acquisition of RSUs and stock options indicates confidence in the company's future prospects.
- The acquisition of 3,990 RSUs and a stock option for 5,277 shares demonstrates a significant personal investment by a key insider.
- The grant of equity aligns the director's interests with those of shareholders.
Risks
- The vesting of RSUs and stock options is contingent on continued service, meaning a departure before June 22, 2027, would result in forfeiture.
- The stock option has a relatively high exercise price of $68.92, suggesting it will only be profitable if the stock price significantly increases.
Future Outlook
The vesting of the RSUs and stock options on June 22, 2027, is a key future event, contingent on continued service. The stock option's exercise price of $68.92 suggests an expectation of significant stock price appreciation.
Industry Context
StockSavvy.ai notes that insider equity grants and option acquisitions are common in the biotechnology sector as a means to attract and retain executive talent and align their interests with long-term company growth and value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Fred Hassan granted a limited power of attorney to specific individuals to execute SEC forms on his behalf, including Forms 3, 4, 5, and Schedules 13D/13G. | 07/18/2025 | Standard practice for facilitating timely and accurate SEC filings by insiders. |
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively, indicating insider confidence, but the direct financial impact is contingent on future stock performance and vesting.
Next Steps
- Continued service by Fred Hassan as a director through June 22, 2027, to ensure vesting of RSUs and stock options.
- Monitoring of BridgeBio Pharma's stock performance relative to the $68.92 stock option exercise price.
Key Dates
| Date | Description |
|---|---|
| 06/22/2026 | Transaction Date for acquisition of RSUs and stock options. |
| 06/21/2036 | Expiration date of the stock option. |
| 06/22/2027 | Vesting date for both the RSUs and the stock option. |
| 07/18/2025 | Date of execution for the Power of Attorney. |
Keywords
BridgeBio Pharma, BBIO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, Equity Grant, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.